NCT04975308 · OUTCOME

Overall Survival (OS) in the ITT Population

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer · Source last updated 2026-07-22

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Randomization until death from any cause (estimated as up to 5 years)

What was measured

OS in the ITT population

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2028-05
denom Units Selected: Participants
description: OS in the ITT population
reporting Status: NOT_POSTED
time Frame: Randomization until death from any cause (estimated as up to 5 years)
title: Overall Survival (OS) in the ITT Population
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice